Search
Savara Inc
SVRAAdd to Watchlist
6.220USD
+0.160+2.64%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.27BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.64%
5 Days
+5.42%
1 Month
+17.36%
6 Months
+10.28%
Year to Date
+3.15%
1 Year
+184.02%
Key Figures
6.100Open
6.260High
1.53MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.75%Turnover Ratio
6.060Prev. Close
6.070Low
6.99MTurnover
LossP/E Static
7.24P/B
0.00%Div Yield TTM
-63.01%ROA
7.00552wk High
1.00Volume Ratio
-95.88MNet Profit
204.92MShares
-0.5583EPS TTM
0.26Beta
-79.95%ROE
1.92552wk Low
3.14%Amplitude
--Gross Margin
1.27BMarket Cap
4.16Reward/Risk
3.45%Risk Rate
TradingKey Stock Score of Savara Inc
Currency: USD Updated: 2026-07-02Key Insights
Savara Inc's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 63 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.94.In the medium term, the stock price is expected to remain stable.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Savara Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Savara Inc Highlights
StrengthsRisks
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Fairly Valued
The company’s latest PE is -11.14, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 213.87M shares, increasing 8.22% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 159.22K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.32.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
10.938
Target Price
+80.49%
Upside Space
Savara Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Savara Inc Info
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Ticker SymbolSVRA
CompanySavara Inc
CEOPauls (Matthew)
Websitehttps://savarapharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Savara Inc (SVRA)?
The current price of Savara Inc (SVRA) is 6.22.
What is the symbol of Savara Inc?
The ticker symbol of Savara Inc is SVRA.
What is the 52-week high of Savara Inc?
The 52-week high of Savara Inc is 7.00.
What is the 52-week low of Savara Inc?
The 52-week low of Savara Inc is 1.93.
What is the market capitalization of Savara Inc?
The market capitalization of Savara Inc is 1.27B.
Is Savara Inc (SVRA) currently rated as Buy, Hold, or Sell?
According to analysts, Savara Inc (SVRA) has an overall rating of Buy, with a price target of 10.94.
What is the Earnings Per Share (EPS TTM) of Savara Inc (SVRA)?
The Earnings Per Share (EPS TTM) of Savara Inc (SVRA) is -0.53.